Avadel Pharmaceuticals Provides Comment on Recent Trading Activity
April 26, 2022 07:30 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a...
Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting
April 25, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
Results from patient preference questionnaire indicate that people with narcolepsy preferred the once-nightly over the twice-nightly dosing regimen for oxybatesNocturnal adverse event questionnaires...
Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial
April 06, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared to placebo in adults with narcolepsyNew data bolster positive primary endpoint...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
March 22, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief...
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 17, 2022 07:00 ET
|
Avadel Pharmaceuticals plc
FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support potential commercial launch Expanded the robust portfolio of data supporting the potential impact of...
Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate Affairs
March 14, 2022 16:30 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 17th
March 14, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a...
Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022
March 11, 2022 07:00 ET
|
Avadel Pharmaceuticals plc
Discrete choice experiment demonstrated that number of doses was the most important attribute driving patient and clinician preference for oxybate therapy, with once-nightly dosing strongly preferred...
Avadel Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
March 10, 2022 16:30 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief...
Avadel to Present New Clinical Data at World Sleep 2022
March 01, 2022 07:00 ET
|
Avadel Pharmaceuticals plc
Eight abstracts accepted for poster presentation featuring new data from the Phase 3 REST-ON clinical trial of FT218 and the RESTORE open-label extension/switch study of FT218 in addition to discrete...